NewAmsterdam Pharma (NAMS) Fundamental Analysis: Revenue, Earnings & Valuation

5.06 / 10

Netural

Fundamental assessment rates NAMS at 5.1/10, indicating average strength. Positive drivers include inventory turnover, accounts receivable turnover, fixed‑asset turnover and interest coverage. Negative aspects are high income‑tax‑to‑profit ratio and weak revenue‑to‑market‑value, limiting upside.

Analysis Checks(8/10)

Revenue-MV

Value-9.55

Score1/3

Weight17.81%

1M Return5.06%

Total operating revenue (YoY growth rate %)

Value-50.61

Score2/3

Weight1.78%

1M Return0.58%

Inventory turnover ratio

Value106.57

Score3/3

Weight-1.91%

1M Return-0.67%

Accounts receivable turnover ratio

Value23.61

Score2/3

Weight-1.89%

1M Return-0.65%

PB-ROE

Value3.94

Score2/3

Weight37.66%

1M Return8.98%

Income tax / Total profit (%)

Value22.35

Score0/3

Weight-4.29%

1M Return-1.54%

Fixed assets turnover ratio

Value72.01

Score3/3

Weight2.51%

1M Return0.79%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight-2.13%

1M Return-0.73%

Cost of sales ratio (%)

Value57.03

Score2/3

Weight-2.09%

1M Return-0.74%

Asset-MV

Value-0.55

Score3/3

Weight52.55%

1M Return13.09%

Is NAMS undervalued or overvalued?

NAMS scores 5.06/10 on fundamentals and holds a Fair valuation at present. Backed by its -28.29% ROE, -905.74% net margin, -16.91 P/E ratio, 5.04 P/B ratio, and 32.81% earnings growth, these metrics solidify its Netural investment rating.